Navigation Links
Transdel Pharmaceuticals to Present at Cowen and Company's 28th Annual Health Care Conference
Date:3/18/2008

LA JOLLA, Calif., March 18 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically administered medications, today announced that Dr. Juliet Singh, President and Chief Executive Officer, will present at Cowen and Company's 28th Annual Health Care Conference on Thursday, March 20, 2008 at 10:15 a.m. Eastern Time at The Marriott Copley Place in Boston, MA.

Dr. Singh will discuss the Company's business developments to date including the recent submission of the Phase 3 clinical study of Ketotransdel(TM) to the FDA.

Interested parties can access a live audio webcast and accompanying slide presentation via the Internet by visiting the Investor Relations section of the Company's Web site at http://www.transdelpharma.com. An archived presentation will be available on the Web site for 30 days.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) is a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically delivered medications. The Company's lead topical drug, Ketotransdel(TM), utilizes the Company's innovative patented proprietary Transdel(TM) cream formulation technology to facilitate the passage of ketoprofen, an NSAID, through the skin barrier to reach targeted underlying tissue where the drug exerts its prolonged localized anti-inflammatory and analgesic effect. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management and other therapeutic areas.

Safe Harbor Statement

The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

Contact:

John Lomoro

Chief Financial Officer

Transdel Pharmaceuticals, Inc.

858-457-5300


'/>"/>
SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
2. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
3. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
4. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
5. ISTA Pharmaceuticals to Present at the Cowen & Company 28th Annual Health Care Conference
6. SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results
7. Onyx Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
9. Drinking Water Association Discusses Pharmaceuticals in Water
10. Genesis Pharmaceuticals Changes Auditors
11. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... ... There is no better place in South Florida to undergo two common ... issue of Consumer Reports focused on heart health. , The magazine gave ... coronary bypass and aortic valve replacement procedures. , Consumer Reports rated Memorial’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG CNS ... Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national conference. ... pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit for ...
(Date:4/24/2017)... ... April 24, 2017 , ... As part of the nationwide Days ... the victims of the Holocaust and Nazi persecution, Center for Medicine after the ... on its CMATH Champions trip to Germany and Poland next week. , The Fourth ...
(Date:4/24/2017)... ... 24, 2017 , ... The California Dental Association Foundation’s two-day volunteer dental clinic, ... people during the April 22-23 event at the San Mateo Event Center. , ... to care, CDA Cares educates the public and policymakers about the importance of good ...
(Date:4/24/2017)... ... April 24, 2017 , ... ALP Nutrition®, a company ... its popular products are now available for purchase on StackedNutrition.com, a popular website ... of premium natural ingredients in making all of its products. These ingredients come ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
(Date:4/19/2017)... -- Companion animal vaccines are ... such as canine, avian and feline. ... as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, ... Vaccines. Attenuated live vaccines are derived from disease-causing ... been weakend under laboratory conditions. Conjugate vaccines are ...
(Date:4/18/2017)... DUBLIN, Ohio , April 18, 2017  Cardinal ... its Non-GAAP 1 fiscal 2017 earnings per share ... 2018 and 2019.  This is in conjunction with this ... Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... EPS from continuing operations will be at the bottom ...
Breaking Medicine Technology: